Multimedialna platforma wiedzy medycznej Internetowa Księgarnia Medyczna Kalendarium Konferencji
Kardiologia Polska (Polish Heart Journal)
MENU
Shortcuts Online first Submit an article Reviewers 2020 Zeszyty Edukacyjne Author Guidelines Licence terms

open access

Online first
Original article
Published online: 2021-04-29
View PDF Download PDF file
Get Citation

Association between cardiovascular disease, cardiovascular drug therapy, and in-hospital outcomes in patients with COVID-19: data from a large single-center registry in Poland

Michał Terlecki, Wiktoria Wojciechowska, Marek Klocek, Agnieszka Olszanecka, Katarzyna Stolarz-Skrzypek, Tomasz Grodzicki, Maciej Małecki, Barbara Katra, Aleksander Garlicki, Monika Bociąga-Jasik, Krzysztof Sładek, Andrzej Matyja, Jerzy Wordliczek, Agnieszka Słowik, Tomasz Mach, Katarzyna Krzanowska, Marcin Krzanowski, Paweł Stręk, Piotr Chłosta, Piotr Hydzik, Mariusz Korkosz, Tadeusz Popiela, Maciej Pilecki, Artur Gądek, Marek Rajzer
Pubmed: 33926173

open access

Online first
Original article
Published online: 2021-04-29

Abstract

ABSTRACT Background: COVID-19 recently became one of the leading causes of death worldwide, similar to cardiovascular disease (CVD). Coexisting CVD may influence the prognosis of patients with COVID-19. Aims: To analyze the impact of CVD and use of cardiovascular drugs on the in-hospital course and mortality of patients with COVID-19. Methods: We retrospectively studied data for consecutive patients admitted to our hospital, with COVID-19 between March 6th and October 15th, 2020. Results: 1729 patients (median (Q1 - Q3) age 63 (50-75) years; women 48.8%) were included. Overall, in-hospital mortality was 12.9%. The most prevalent CVD was arterial hypertension (56.1%), followed by hyperlipidemia (27.4%), diabetes mellitus (DM) (25.7%), coronary artery disease (16.8%), heart failure (HF) (10.3%), atrial fibrillation (13.5%), and stroke (8%). Angiotensin converting enzyme inhibitors or angiotensin receptor blockers (ACEIs/ARBs) were used in 25.0% of patients, β-blockers in 40.7%, statins in 15.6%, and antiplatelet therapy in 19.9%. Age over 65 years (odds ratio [OR] 6.4, 95% CI 4.3–9.6), male sex (OR 1.4, 95% CI 1.1–2.0), pre-existing DM (OR 1.5, 95% CI 1.1–2.1), and HF (OR 2.3, 95% CI 1.5–3.5) were independent predictors of in-hospital death, whereas treatment with ACEIs/ARBs (OR 0.4, 95% CI 0.3–0.6), β-blockers (OR 0.6, 95% CI 0.4–0.9), statins (OR 0.5, 95% CI 0.3–0.8), or antiplatelet therapy (OR 0.6, 95% CI 0.4–0.9) was associated with lower risk of death. Conclusion: Among cardiovascular risk factors and diseases, HF and DM appeared to increase in-hospital COVID-19 mortality, whereas the use of cardiovascular drugs was associated with lower mortality.

Abstract

ABSTRACT Background: COVID-19 recently became one of the leading causes of death worldwide, similar to cardiovascular disease (CVD). Coexisting CVD may influence the prognosis of patients with COVID-19. Aims: To analyze the impact of CVD and use of cardiovascular drugs on the in-hospital course and mortality of patients with COVID-19. Methods: We retrospectively studied data for consecutive patients admitted to our hospital, with COVID-19 between March 6th and October 15th, 2020. Results: 1729 patients (median (Q1 - Q3) age 63 (50-75) years; women 48.8%) were included. Overall, in-hospital mortality was 12.9%. The most prevalent CVD was arterial hypertension (56.1%), followed by hyperlipidemia (27.4%), diabetes mellitus (DM) (25.7%), coronary artery disease (16.8%), heart failure (HF) (10.3%), atrial fibrillation (13.5%), and stroke (8%). Angiotensin converting enzyme inhibitors or angiotensin receptor blockers (ACEIs/ARBs) were used in 25.0% of patients, β-blockers in 40.7%, statins in 15.6%, and antiplatelet therapy in 19.9%. Age over 65 years (odds ratio [OR] 6.4, 95% CI 4.3–9.6), male sex (OR 1.4, 95% CI 1.1–2.0), pre-existing DM (OR 1.5, 95% CI 1.1–2.1), and HF (OR 2.3, 95% CI 1.5–3.5) were independent predictors of in-hospital death, whereas treatment with ACEIs/ARBs (OR 0.4, 95% CI 0.3–0.6), β-blockers (OR 0.6, 95% CI 0.4–0.9), statins (OR 0.5, 95% CI 0.3–0.8), or antiplatelet therapy (OR 0.6, 95% CI 0.4–0.9) was associated with lower risk of death. Conclusion: Among cardiovascular risk factors and diseases, HF and DM appeared to increase in-hospital COVID-19 mortality, whereas the use of cardiovascular drugs was associated with lower mortality.

Full Text:

View PDF Download PDF file
Get Citation
About this article
Title

Association between cardiovascular disease, cardiovascular drug therapy, and in-hospital outcomes in patients with COVID-19: data from a large single-center registry in Poland

Journal

Kardiologia Polska (Polish Heart Journal)

Issue

Online first

Article type

Original article

Published online

2021-04-29

Pubmed

33926173

Authors

Michał Terlecki
Wiktoria Wojciechowska
Marek Klocek
Agnieszka Olszanecka
Katarzyna Stolarz-Skrzypek
Tomasz Grodzicki
Maciej Małecki
Barbara Katra
Aleksander Garlicki
Monika Bociąga-Jasik
Krzysztof Sładek
Andrzej Matyja
Jerzy Wordliczek
Agnieszka Słowik
Tomasz Mach
Katarzyna Krzanowska
Marcin Krzanowski
Paweł Stręk
Piotr Chłosta
Piotr Hydzik
Mariusz Korkosz
Tadeusz Popiela
Maciej Pilecki
Artur Gądek
Marek Rajzer

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By VM Media Sp. z o.o. VM Group Sp.k., ul. Świętokrzyska 73 , 80–180 Gdańsk, Poland

phone:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: viamedica@viamedica.pl